Measurement of dyspnea ratings during exercise

Dyspnea: Mechanisms, Measurement and Management

Volumn , Issue , 2005, Pages 167-182

  Mahler, Donald A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85031353013     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Baird JC, Noma E. Fundamentals of Scaling and Psychophysics. New York: Wiley Interscience, 1978.
2. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1185-1189.
3. KillianK. Nature of breathlessness and itsmeasurement. In: JonesNL, KillianKJ, eds. Breathlessness: the Campbell Symposium, Hamilton, Ontario, 1992: 74-87.
4. El-Manshawi A, Killian KJ, Sumemrs E, Jones NL. Breathlessness during exercise with and without resistive loading. J Appl Plysiol 1986; 61: 896-905.
5. Leblanc P, Bowie DM, Summers E, Jones NL, Killian KJ. Breathlessness and exercise in patients with cardiorespiratory disease. Am Rev Respir Dis 1986; 133: 21-25.
6. Mahler DA, Faryniarz K, Lentine T, Ward, Olmstead EM, O’Connor GT. Measurement of breathlessness during exercise in asthmatics: predictor variables, reliability, and responsiveness. Am Rev Respir Dis 1991; 144: 39-44.
7. Killian KJ, Summers E, Jones NL, Campbell EJM. Dyspnea and leg effort during incremental cycle egrometry. Am Rev Respir Dis 1992; 145: 1339-1345.
8. American Thoracic Society. Dyspnea-assessment, mechanisms, and management. A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
9. Killian KJ. The objective measurement of breathlessness. Chest 1985; 88(suppl): 84S-90S.
10. Mahler DA. The measurement of dyspnea during exercise in patients with lung disease. Chest 1992; 101(suppl): 242S-247S.
11. Mahler DA, Jones PW, Guyatt GH. Clinical measurement of dyspnea. In: Mahler DA, ed. Dyspnea. New York: Marcel Dekker, Inc., 1998: 149-198.
12. Butland RJA, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. BMJ 1982; 284: 1607-1608.
13. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
14. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. Six-minute walk distance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1522-1527.
15. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-1282.
16. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT. Bronchodilators in chronic airflow limitation. Am Rev Respir Dis 1987; 135: 1069-1074.
17. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
18. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.
19. Liesker JJW, Wijkstra PJ, Ten Hacken NHT, Koeter GH, Postma DS, Kerstjens HAM. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
20. Mahler DA. Dyspnea. In: Celli BR, ed. Pharmacotherapy of COPD. Vol. 182. New York: Marcel Dekker, Inc., 2003: 145-158.
21. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of diability in patients with chronic airways obstruction. Thorax 1992; 47: 1019-1024.
22. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary diesaes. Thorax 1999; 54: 213-222.
23. Zeballos RJ, Weisman IM. Modalities of clinical exercise testing. In: Weisman IM, Zeballos RJ, eds. Clinical Exercise Testing. Progress in Respiratory Research. Vol. 32. Basel: Karger, 2002: 30-42.
24. Wadbo M, Lofdahl CG, Larsson K, Skoogh BE, Tornling G, Arwestrom E, Bengtsson T, Strom K. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138-1146.
25. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-217.
26. Mahler DA. Pulmonary rehabilitation. Chest 1998; 113: 263S-268S.
27. ACCP-AACVPR Pulmonary Rehabilitation Panel. Pulmonary rehabilitation: joint ACCP/AACVPR evidence based guidelines. Chest 1997; 112: 1363-1396.
28. Franco MJ, Olmstead EM, Tosteson ANA, Lentine T, Ward J, Mahler DA. Comparison of dyspnea ratings during submaximal constant work exercise with incremental testing. Med Sci Sports Exerc 1998; 30: 479-482.
29. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
30. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161: 1897-1901.
31. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest 2003; 123: 1810-1816.
32. Borg G. Borg’s Perceived Exertion and Pain Scales. Champaign, IL: Human Kinetics, 1998.
33. Borg GAV. Psychological bases of perceived exertion. Med Sci Sport Exerc 1982; 14: 377-381.
34. Killian KJ, LeBlanc P, Martin DH, Summers E, Jones NL, Campbell EJM. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992; 146: 935-940.
35. Hamilton AL, Killian KJ, Summers E, Jones NL. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996; 110: 1255-1263.
36. O’Donnell DE, McGuire MA, Samis L, Webb KA. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152: 2005-2013.
37. Mahler DA. Measurement of dyspnea. In: Donner CF, Ambrosino N, Goldstein R, eds. Pulmonary Rehabilitation: Efficacy and Scientific Basis. London: Arnold, 2004, In press.
38. Horowitz MB, Littenberg B, Mahler DA. Dyspnea ratings for prescribing exercise intensity in patients with chronic obstructive pulmonary disease. Chest 1996; 109: 1169-1175.
39. Mejia R, Ward J, Lentine T, Mahler DA. Target dyspnea ratings predict expected oxygen consumption as well as target heart rate values. Am J Respir Crit Care Med 1999; 159: 1485-1489.
40. Mahler DA, Ward J, Mejia-Alfaro R. Stability of dyspnea ratings after exercise training in patients with COPD. Med Sci Sports Exerc 2003; 35: 1083-1087.
41. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nurs Res 1989; 38: 286-288.
42. Wilson RC. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. Clin Sci 1989; 76: 277-282.
43. Muza SR, Silverman MT, Gilmore GC, Hellerstein HK, Kelsen SG. Comparison of scales used to quantitate the sense of effort to breathe in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 141: 909-913.
44. Mahler DA, Fierro-Carrion G, Baird JC. Mechanisms and measurement of exertional dyspnea. In: Weisman IM, Zeballos RJ, eds. Clinical Exercise Testing. Progress in Respiratory Research. Basel: Karger, 2002: 72-80.
45. Mahler DA, Harver A. Prediction of peak oxygen consumption in obstructive airway disease. Med Sci Sports Exerc 1988; 20: 574-578.
46. Man WDC, Soliman MGG, Gearing J, Radford SG, Rafferty GF, Gray BJ, Polkey MI, Moxham J. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 562-567.
47. O’Donnell DE, Chau LKL, Webb KA. Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol 1998; 84: 2000-2009.
48. Fierro-Carrion G, Mahler DA, Ward J, Baird JC. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004; 125: 77-84.
49. Harty HR, Heywood P, Adams L. Comparison between continuous and discrete measurements of breathlessness during exercise in normal subjects using a visual anlogue scale. Clin Sci 1993; 85: 229-236.
50. Mahler DA, Mejia-Alfaro R, Ward J, Baird JC. Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J Appl Physiol 2001; 90: 2188-2196.
51. Teramoto S, Fukuchi Y, Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 1993; 103: 1774-1782.
52. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophyloline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-273.
53. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
54. Ayers ML, Mejia R, Ward J, Lentine T, Mahler DA. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001; 17: 1132-1137.
55. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc 1994; 26: 1078-1081.
56. Mahler DA. Dyspnea: diagnosis and management. Clin Chest Med 1987; 8: 215-230.